Compare BBLG & PPCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBLG | PPCB |
|---|---|---|
| Founded | 2004 | 2007 |
| Country | United States | Australia |
| Employees | 2 | 2 |
| Industry | Industrial Specialties | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.3M |
| IPO Year | N/A | N/A |
| Metric | BBLG | PPCB |
|---|---|---|
| Price | $1.28 | $0.07 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.5K | ★ 1.3M |
| Earning Date | 05-13-2026 | 05-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.70 | $0.07 |
| 52 Week High | $5.98 | $10.69 |
| Indicator | BBLG | PPCB |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 27.55 |
| Support Level | $1.11 | N/A |
| Resistance Level | $1.40 | $0.13 |
| Average True Range (ATR) | 0.05 | 0.01 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 16.74 | 0.91 |
Bone Biologics Corp a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. It is a clinical-stage entity. The production and marketing of its products and ongoing research and development activities are subject to extensive regulation by numerous governmental authorities in the United States.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.